Clinical Infectious Diseases
cidjournal.bsky.social
The world's leading journal on infectious diseases. Clinical ID, public health, microbiology, and everything in-between. Official publication of @idsainfo.bsky.social
👤 Joined on 24 October 2023
22087
Followers
1
Following
1148
Total Posts
📜 Kullanıcı Geçmişi
- 24 Eki 2023, 19:28
🎉 Bluesky'e katıldı - İlk kullanıcı adı:
@cidjournal.bsky.social - 10 Kas 2023, 16:13
🔄 Profil bilgileri güncellendi
🚫 Blokladığı Kullanıcılar
❤️ Beğendiği Gönderiler
On IDSA’s & HIVMA’s Science Speaks: Learn more about the efficacy of switching to doravirine/islatravir, how immunocompromised individuals hospitalized with COVID-19 remain at increased mortality risk and other research in @jidjournal.bsky.social to inform clinical practice. https://bit.ly/4AYYFzi
Show PostIDSA has established a Journals Reader Panel where readers of cidjournal.bsky.social, ofidjournal.bsky.social and jidjournal.bsky.social can give direct feedback to our editors. Apply to join by March 31 to engage directly with editors, learn about new journal initiatives and more: bit.ly/406h4ZG
Show PostIDSA has established a Journals Reader Panel where readers of cidjournal.bsky.social, ofidjournal.bsky.social and jidjournal.bsky.social can give direct feedback to our editors. Apply to join by March 31 to engage directly with editors, learn about new journal initiatives and more: bit.ly/406h4ZG
Show Post
I heard you calling, on the megaphone. You wanna see the micro. As legend has it, you like the PO. academic.oup.com/cid/advance-... 🫶 Behind a paywall but LMK and I can DM you the full proof.
Show Post
Therapeutic Drug Monitoring of Long-Acting Cabotegravir and Rilpivirine in a National Cohort of People With #HIV: First Results From the ANRS-MIE CARLAPOP Study academic.oup.com/cid/advance-... (subscription req for full text) @cidjournal.bsky.social
Show Post